ClinicalTrials.gg
CompletedNCT05305534Updated Sep 24, 2025

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

An observational study in Blood Disease, sponsored by QIAGEN Gaithersburg, Inc. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,142
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Hematologic Diseases with a site in United Kingdom — 7 open to participants now, 21 under way, 17 of them phase 3. Hematologic Diseases · United Kingdom.

Started
2023
with 1 other
Observational
8 of 70
1 open now
Registered
65th of 70
by date

Among the 70 studies in Hematologic Diseases with a site in United Kingdom, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 65th registered.

Hematologic Diseases

610 studies on the registry are indexed under Hematologic Diseases; 109 are open to participants now.

Browse Hematologic Diseases studies →

Open to participants now

7 of the 70 studies in Hematologic Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 73 Hematologic Diseases studies recruiting now, 46 (63%) set no upper age limit and 23 (32%) stop at 75 or younger; 28 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Hematologic Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods

Read the detailed description

This multicenter study aims to evaluate the performance of QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel with another validated comparator method.

03

Conditions studied

  • Blood Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients suspected of bloodstream infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive (as identified through Gram stain) blood culture media specimens cultured within bottle types listed in IFU.
  • Residual and de-identified specimens.
  • Specimen from subject who has not previously been enrolled.
  • Fresh prospectively collected specimens tested within 24 hours of initial blood culture bottle positivity.
  • Frozen prospectively collected specimens frozen within 24 hours of initial blood culture bottle positivity.
  • Minimum 1.5 mL volume available
  • In stage 2 - Pure colony isolates of Bacilli, Actinobacteria, fungi (except Fusarium), Enterobacterales, Pseudomondales, Nesseriales, Pasteurellales, Bacterioidales, or Xanthomonadales.

Exclusion criteria

Exclusion Criteria:

  • Positive Blood Culture specimens inoculated with a sample type other than Blood (i.e. Paracentesis, or other body fluids)
  • Specimens collected off-label from the manufacturer's package insert (e.g., less than the minimum required blood volume was collected).
  • Frozen specimens which are unable to be cultured after thawing.
  • Specimen from subject previously enrolled
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,142 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • DeviceQIAstat-Dx® BCID GN and GPF Plus AMR Panels

    The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested

06

What researchers measure

Primary outcomes

  1. PPA

    positive percentage agreement

    Time frame: 6 moths

  2. NPA

    negative percentage agreement

    Time frame: 6 moths

07

Study locations

1 site
  • QIAGEN
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — all samples are residual and anonymized

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Apr 2025, 16 months.

Of 64 observational studies under Hematologic Diseases, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 78. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
Mar 31, 2022
StartActual
Dec 1, 2023
Primary completionActual
Apr 10, 2025
CompletionActual
Aug 25, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05305534
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Dec 1, 2023
Primary completion
Apr 10, 2025
Completion
Aug 25, 2025
Last update
Sep 24, 2025

Study contacts

Sarah Johnson
principal investigator · QIAGEN Gaithersburg, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion